Sold as Vfend, Voriconazole. Every FDA application for this active ingredient: 6 branded and 28 generic.
As of Nov 15, 2026, FDA lists 34 applications for Voriconazole (sold as Vfend, Voriconazole), first approved May 24, 2002, with 6 new uses approved and 0 published complete response letters.
| Voriconazole | Part D | $11.5M | -20% | 13,661 |
| Vfend IV | Part D | $13K | -78% | 35 |
| Vfend IV | Part B | $4K | +2523% | 64 |
| Vfend | Part D | $0K | -100% | 0 |
| May 24, 2002 | VfendNDA 21266 · New molecular entity | Pf Prism Cv | 42 | Marketed |
| May 24, 2002 | VfendNDA 21267 · New formulation or manufacturer | Pf Prism Cv | 43 | Marketed |
| Nov 14, 2003 | VfendNDA 21464 · TYPE 6 | Pfizer | 0 | Marketed |
| Nov 14, 2003 | VfendNDA 21466 · TYPE 6 | Pfizer | 0 | Marketed |
| Dec 19, 2003 | VfendNDA 21630 · New dosage form | Pf Prism Cv | 38 | Marketed |
| Apr 22, 2010 | VoriconazoleANDA 90547 | Mylan Pharms Inc | 14 | Marketed |
| Dec 12, 2011 | VoriconazoleANDA 200265 | Sandoz Inc | 11 | Marketed |
| Apr 6, 2012 | VoriconazoleANDA 91658 | Teva Pharms | 6 | Discontinued |
| May 30, 2012 | VoriconazoleANDA 90862 | Sandoz Inc | 14 | Marketed |
| May 28, 2013 | VoriconazoleANDA 202361 | Rising | 2 | Discontinued |
| Sep 2, 2015 | VoriconazoleANDA 203503 | Glenmark Pharms Ltd | 11 | Marketed |
| Jan 22, 2016 | VoriconazoleANDA 206837 | Aurobindo Pharma Ltd | 0 | Marketed |
| Mar 23, 2016 | VoriconazoleANDA 206398 | Almaject | 5 | Discontinued |
| Apr 13, 2016 | VoriconazoleANDA 205034 | Amneal Pharms | 8 | Marketed |
| May 24, 2016 | VoriconazoleANDA 206181 | Ajanta Pharma Ltd | 10 | Marketed |
| May 24, 2016 | VoriconazoleANDA 206762 | Rising | 0 | Marketed |
| May 24, 2016 | VoriconazoleANDA 207371 | Chartwell Rx | 6 | Marketed |
| May 24, 2016 | VoriconazoleANDA 206747 | Cadila | 13 | Marketed |
| May 31, 2016 | VoriconazoleANDA 206799 | Novel Labs Inc | 7 | Marketed |
| Aug 8, 2016 | VoriconazoleANDA 206654 | Prinston | 0 | Marketed |
| Sep 7, 2016 | VoriconazoleANDA 207049 | Epic Pharma LLC | 0 | Marketed |
| Mar 9, 2017 | VoriconazoleNDA 208562 · New formulation or manufacturer | Hikma | 5 | Marketed |
| Jul 16, 2018 | VoriconazoleANDA 208983 | Zydus Pharms | 0 | Marketed |
| Nov 30, 2018 | VoriconazoleANDA 211661 | Hainan Poly | 5 | Marketed |
| Mar 31, 2020 | VoriconazoleANDA 211099 | Gland | 8 | Marketed |
| May 9, 2022 | VoriconazoleANDA 214516 | Meitheal | 4 | Marketed |
| Oct 11, 2022 | VoriconazoleANDA 210849 | Pharmobedient | 0 | Discontinued |
| Feb 2, 2023 | VoriconazoleANDA 212162 | Eugia Pharma | 0 | Discontinued |
| Mar 9, 2023 | VoriconazoleANDA 211264 | Ubi | 0 | Marketed |
| Jan 2, 2024 | VoriconazoleANDA 216805 | Zhejiang Poly Pharm | 1 | Marketed |
| Apr 3, 2024 | VoriconazoleANDA 218533 | Aspiro | 1 | Marketed |
| Aug 8, 2025 | VoriconazoleANDA 211598 | Hetero Labs Ltd V | 1 | Marketed |
| Nov 14, 2025 | VoriconazoleANDA 220043 | Hainan Poly Pharm | 1 | Marketed |
| May 5, 2026 | VoriconazoleANDA 220078 | Zhejiang Novus | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer
Mylan Pharms Inc
Hikma
Zydus Pharms
Eugia Pharma